Pulse Biosciences Presents Data From Several Clinical Studies of Nano-Pulse Stimulation Technology to Clear Skin Lesions at the 2019 ASDS Annual Meeting

Posted in Biotech

October 18, 2019 • 2 min read

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company bringing to market its proprietary CellFX System harnessing Nano-Pulse Stimulation (NPS) technology, today announced that it will present results of three clinical studies demonstrating high clearance rates across its benign skin lesion portfolio during the upcoming American Society for Dermatologic Surgery (“ASDS”)...

Independent Drug-Pricing Assessment Finds Vascepa Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke and Cardiac Death

Posted in Biotech

October 17, 2019 • 2 min read

Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that an independent organization that evaluates pricing of prescription drugs has issued its final report assessing the cost-effectiveness of Vascepa (icosapent ethyl) capsules...